ALNY: Alnylam Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ALNY: Alnylam Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 18,376.02
Enterprise Value ($M) 19,961.35
Book Value ($M) -220.64
Book Value / Share -1.74
Price / Book -83.28
NCAV ($M) -1,067.83
NCAV / Share -8.44
Price / NCAV -17.21

Profitability (mra)
Return on Invested Capital (ROIC) -0.18
Return on Assets (ROA) -0.13
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 2.99
Current Ratio 3.08

Balance Sheet (mrq) ($M)
Current Assets 2,982.70
Assets 3,829.88
Liabilities 4,050.52
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1,828.29
Operating Income -282.18
Net Income -440.24
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 104.16
Cash from Investing -336.35
Cash from Financing 172.13

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 9.52 3.80
02-09 13G/A Fmr Llc 8.24 -23.63
02-09 13G/A Capital World Investors 13.10 -1.18
02-09 13G/A Wellington Management Group Llp 5.78 15.83
01-29 13G/A Baillie Gifford & Co 5.55 -25.94
01-26 13G/A BlackRock Inc. 6.80 -1.37

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K _____________________________________________________________________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Se
2023-08-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Ju
2023-05-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Ma

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-18 94,621 306,173 30.90
2024-04-17 69,903 250,844 27.87
2024-04-16 76,961 146,188 52.65
2024-04-15 80,203 203,665 39.38

(click for more detail)

Similar Companies
ALKS – Alkermes plc ALLK – Allakos Inc.
ALLO – Allogene Therapeutics, Inc. ALVR – AlloVir, Inc.
ALXO – ALX Oncology Holdings Inc.


Financial data and stock pages provided by
Fintel.io